DBVT

DBV Technologies S.A. is a French clinical-stage biopharmaceutical company developing treatments for food allergies. The company's Viaskin technology platform is designed to deliver allergen-specific immunotherapy through an epicutaneous patch applied to intact skin. DBV's lead product candidate, Viaskin Peanut, is being developed for the treatment of peanut allergy in children and adults. The company is working to address the significant unmet medical need in food allergy treatment, where current options are limited and the population of affected individuals continues to grow.